Internal Medicine, Nephrology · Stockton, CA
NPI
1083611594
Since 2005
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1805 N California St, Ste 303
Stockton, CA, 95204
Phone (209) 888-4340
Groups this clinician bills Medicare through
Medicare paid, 2024
$615K
4,604 services
Medicare patients, 2024
891
Average age 74
Drug cost, 2024
$901K
5,810 prescriptions
Company payments, 2025
$493
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Randeep S Bajwa was code 99232 (hospital e&m - subsequent), 1,261 times for 334 patients. In total Randeep S Bajwa billed 4,604 services in 26 codes, and Medicare paid $615K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-08-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 1,261 | 334 | $66.70 | $84K |
| 90960 ESRD Related Services (not dialysis) | Office | 840 | 108 | $295.68 | $248K |
| 99214 Office E&M - Established | Office | 704 | 369 | $75.04 | $53K |
| 99233 Hospital E&M - Subsequent | Facility | 510 | 179 | $100.24 | $51K |
| 99223 Hospital E&M - Initial | Facility | 352 | 291 | $145.83 | $51K |
| 99213 Office E&M - Established | Office | 263 | 186 | $54.83 | $14K |
| 90966 ESRD Related Services (not dialysis) | Office | 157 | 23 | $246.44 | $39K |
| 90961 ESRD Related Services (not dialysis) | Office | 138 | 48 | $249.71 | $34K |
| 90935 Hemodialysis | Facility | 96 | 44 | $60.09 | $5,768 |
| 99205 Office E&M - New | Office | 73 | 73 | $171.52 | $13K |
| 90962 ESRD Related Services (not dialysis) | Office | 43 | 27 | $173.96 | $7,480 |
| 99215 Office E&M - Established | Office | 36 | 31 | $130.70 | $4,705 |
| 99291 Critical Care E&M | Facility | 17 | 17 | $177.46 | $3,017 |
By year: 2022 $584K for 4,776 services; 2023 $571K for 4,270 services; 2024 $615K for 4,604 services.
Medicare prescription drug claims, 2024
In 2024, the drug Randeep S Bajwa prescribed most often to Medicare patients was Calcitriol, with 1,030 prescriptions and refills. In total Randeep S Bajwa wrote 5,810 Medicare prescriptions that cost $901K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Calcitriol Generic | 1,030 | 2,556 | 314 | $16K |
| Amlodipine Besylate Generic | 377 | 999 | 135 | $2,534 |
| Losartan Potassium Generic | 337 | 971 | 122 | $3,055 |
| Hydralazine Hcl Generic | 321 | 772 | 110 | $4,953 |
| Metoprolol Succinate Generic | 252 | 653 | 88 | $4,998 |
| Furosemide Generic | 248 | 566 | 72 | $1,707 |
| Calcium Acetate Generic | 201 | 431 | 70 | $14K |
| Lisinopril Generic | 199 | 514 | 69 | $1,569 |
| Allopurinol Generic | 181 | 455 | 61 | $1,592 |
| Sevelamer Carbonate Generic | 149 | 290 | 43 | $45K |
| Farxiga Dapagliflozin Propanediol | 143 | 289 | 44 | $151K |
| Hydrochlorothiazide Generic | 133 | 331 | 43 | $804 |
| Carvedilol Generic | 121 | 297 | 37 | $952 |
| Potassium Chloride Generic | 109 | 254 | 42 | $1,699 |
| Bumetanide Generic | 106 | 240 | 33 | $3,405 |
Brand drugs: - claims; generic drugs: 5,148 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Randeep S Bajwa $493 ($493 in general payments such as food, travel and fees) from 12 companies. The largest payer was Amgen Inc. with $98.94.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 4 | $98.94 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 4 | $96.82 |
| Novo Nordisk Inc NVO | 2 | $57.47 |
| Vifor Pharma, Inc. | 2 | $47.58 |
| Fresenius USA Marketing, Inc. | 2 | $40.72 |
| Mozarc Medical US LLC | 1 | $32.55 |
| Mallinckrodt Hospital Products Inc. | 1 | $23.56 |
| Travere Therapeutics, Inc. TVTX | 1 | $23.13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $22.54 |
| Apellis Pharmaceuticals, Inc. APLS | 1 | $17.79 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.